Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib ac...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambale, Elisabetta, Carella, Consiglia, Amerio, Paolo, Buttitta, Fiamma, Patea, Rosa Lucia, Natoli, Clara, De Tursi, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449169/
https://www.ncbi.nlm.nih.gov/pubmed/28579838
http://dx.doi.org/10.2147/IMCRJ.S134944

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5449169/
https://www.ncbi.nlm.nih.gov/pubmed/28579838
http://dx.doi.org/10.2147/IMCRJ.S134944

Ejemplares similares